PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “EOSINOPHIL COUNT”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 37 records · Page 2Linked to original sources
PubMed2004

Major quantitative trait locus for eosinophil count is located on chromosome 2q.

BACKGROUND: Eosinophils are granulocytic white blood cells implicated in asthma and atopic disease. The degree of eosinophilia in the blood of patients with asthma correlates with the severity of asthmatic symptoms. Quantitative trait loci (QTL) linkage analysis of eosinophil count may be a more powerful strategy of mapping genes involved in asthma than linkage analysis using affected relative pairs. OBJECTIVE: To identify QTLs responsible for variation in eosinophil count in adolescent twins. METHODS: We measured eosinophil count longitudinally in 738 pairs of twins at 12, 14, and 16 years of age. We typed 757 highly polymorphic microsatellite markers at an average spacing of approximately 5 centimorgans across the genome. We then used multipoint variance components linkage analysis to test for linkage between marker loci and eosinophil concentrations at each age across the genome. RESULTS: We found highly significant linkage on chromosome 2q33 in 12-year-old twins (logarithm of the odds=4.6; P=.000002) and suggestive evidence of linkage in the same region in 14-year-olds (logarithm of the odds=1.0; P=.016). We also found suggestive evidence of linkage at other areas of the genome, including regions on chromosomes 2, 3, 4, 8, 9, 11, 12, 17, 20, and 22. CONCLUSION: A QTL for eosinophil count is present on chromosome 2q33. This QTL might represent a gene involved in asthma pathophysiology.

Adolescent↗
PubMed1975

Six-month follow-up of eosinophil counts in veteran heroin addicts.

Monthly eosinophil counts were taken from 40 patients while they were undergoing narcotic maintenance. The overall results indicate that there was relatively little change in the eosinophil values throughout the six-month period. This hospital found, however, that there was a positive correlation between elevated eosinophil counts and heavy illicit drug use. This seems to indicate a correlation between intravenous drug use and a high eosinophil count.

Adult↗
PubMed1987

Peripheral blood eosinophil counts and bronchial responsiveness.

Bronchial responsiveness (histamine PC20) and peripheral blood eosinophil counts were measured in 23 asthmatic subjects, of whom 14 were atopic and nine non-atopic. In the group as a whole there was an inverse correlation between baseline eosinophil count and histamine PC20 (r = -0.71; p less than 0.001). For atopic subjects a relationship between eosinophil count and histamine PC20 was observed (r = -0.74; p less than 0.01), but there was no correlation between eosinophil count and baseline FEV1 or baseline FEV1 and histamine PC20. For the non-atopic subjects a similar relationship between eosinophil count and histamine PC20 was seen (r = -0.68; p less than 0.05) and a less significant inverse correlation between baseline eosinophil count and baseline FEV1 (r = -0.65; p less than 0.05). These results show a relationship between eosinophil count and non-specific bronchial responsiveness in both atopic and non-atopic asthma.

Adolescent↗
PubMed2001

Surplus value of eosinophil count and ECP to diagnose and monitor asthmatic patients.

BACKGROUND: Eosinophil cationic protein (ESP) is one of the granule proteins in eosinophilic granulocytes. Release of this protein may reflect the activity state of eosinophilic granulocytes in diseased subjects. The purpose of this study was to evaluate the additional value of serum ECP measurement over the eosinophil count, (specific) IgE concentration and CRP concentration in order to evaluate the effects of treatment in patients started on corticosteroids and to distinguish individual patients with asthma from healthy subjects on the basis of laboratory results. METHODS: In a longitudinal study, serial measurements of serum ECP, eosinophil count and other laboratory parameters have been evaluated and compared with spirometry and tests of bronchial hyperresponsiveness in ten asthmatic subjects. The subjects were investigated before therapy was started and 3, 6 and 9 months after the start of therapy with inhaled corticosteroids. Laboratory parameters in the patient group are compared with results obtained from a reference group of apparently healthy subjects (n=223). RESULTS: Statistically significant correlations are observed between blood eosinophil counts and serum ECP concentrations with the hyperresponsiveness tests PC20 (r=0.44 and r=0.46, respectively) and with a decrease in FEV(1) after exercise (r=0.66 and r=0.60, respectively). A significant difference was detected between serum ECP concentrations from the patients' group and from the reference group. However, a wide range of overlapping results was observed between the reference group and the asthmatic patients. CONCLUSIONS: Asthma is a disease which is now more frequently treated by general practitioners. In general practice there is not always the opportunity to evaluate asthma activity by the application of hyperreactivity tests. When hyperreactivity testing is not available, measuring serum ECP concentration or eosinophil blood count would be an alternative method to monitor the effects of corticosteroid treatment. In this study the additional value of serum ECP in addition to the eosinophil count is evaluated to determine the effects of treatment in patients who started with application of corticosteroids. However, because of the analogous correlation coefficients of laboratory parameters with tests regarding hyperresponsiveness, no additional benefit of serum ECP concentration over eosinophil blood count in monitoring the effect of corticosteroids can be detected. The additional value of serum ECP concentrations and eosinophil counts to detect an asthmatic constitution for individual cases is doubtful.

Adrenal Cortex Hormones↗
PubMed1987

The determination of the eosinophil count: comparison of two techniques.

The total eosinophil count obtained by use of the standard hemacytometer is considered by several investigators to be the most reliable method for the determination of the circulating eosinophil levels in the blood because it is believed to be less subject to error than the calculated eosinophil count obtained with Wright stained blood smears from the differential count. We compared the two techniques in outpatients as well as inpatients with and without allergies (total of 514 patients). Our results demonstrate that the eosinophil count by the two methods are similar.

Eosinophils↗
PubMed1989

Falls in peripheral eosinophil counts parallel the late asthmatic response.

Peripheral eosinophil counts were measured at intervals before and after control and allergen inhalation in 14 asthmatic subjects. A relative fall in eosinophil counts was noted 9 h after allergen challenge, in contrast to the diurnal increase seen on the control day (p = 0.005). This fall in eosinophil count correlated strongly with the magnitude of the late asthmatic response (r = -0.72, p = 0.003) and with the changes in bronchial responsiveness to histamine at 3 and 24 h after allergen was given (r = 0.54, p = 0.044 and r = 0.82, p less than 0.001, respectively). The findings demonstrate eosinophil kinetics are related to the occurrence of late-phase reactions and to the associated worsening of bronchial hyperreactivity.

Adult↗
PubMed2006

Significance of eosinophil counting in tumor associated tissue eosinophilia (TATE).

Eosinophils are present in large numbers in some squamous cell carcinomas of the oral cavity. Whilst it is proposed that they have an 'immuno-protective' effect, this remains unproven. The contradictory reports may be due to inconsistencies in eosinophil counting. Eighty-one cases of squamous cell carcinoma (SSC) of oral tongue were examined. Two methods of eosinophil counting were performed. In the first method (classical), the eosinophils were counted per 10 HPF. In the second method (our so-called density method), the highest eosinophil density per surface area was counted for each case. The two methods were correlated. Using the classical method a number of fields in cases ranked low, contained more than 10 eosinophils. Likewise, some moderate cases contained more than 100 eosinophils. There is poor correlation between the classical and density counts. Nevertheless, good correlation between the two methods could be achieved if the boundaries of the classical method are modified. Eosinophils invariably appear in clusters. We feel that an assessment of density may well be better than classical counting, and have more relationship with function.

Eosinophilia↗
PubMed2002

Incidence of peripheral blood eosinophilia and the threshold eosinophile count for indicating hypereosinophilia-associated diseases.

BACKGROUND: A definite threshold of the peripheral blood eosinophile count that indicates the presence of hypereosinophilia-associated diseases has not yet been determined. METHODS: The threshold eosinophile count at which cases of hypereosinophilia-associated diseases (n = 25) can be differentiated from those of bronchial asthma (n = 101) was determined. Then, the incidences of eosinophile counts greater than 1.0 x 10(9)/l or the threshold level, were studied by analysis of 43,805 samples sent to the laboratory, and the diseases associated with the increased counts were determined. RESULTS: The eosinophile count in cases of hypereosinophilia-associated diseases and in those of bronchial asthma were 10.967 +/- 1.680 x 10(9)/l and 0.574 +/- 0.045 x 10(9)/l, respectively (P < 0.001); the threshold was 2.052 x 10(9)/l. The percentages of samples with an eosinophile count of more than 1.0 x 10(9)/l and 2.052 x 10(9)/l were 0.6% and 0.1%, respectively; the latter comprised of 41 samples from 24 patients including eight with hypereosinophilia-associated diseases. The patients with hypereosinophilia-associated diseases had a significantly higher count, and a higher incidence of counts of more than 2.052 x 10(9)/l, than others, including patients with malignancies and symptoms conventionally referred as "atopic diseases". CONCLUSION: Hypereosinophilia-associated diseases are associated with a very high eosinophile count of more than 2.052 x 10(9)/l, which was observed rarely.

Asthma↗
PubMed2006

Correlation of immunoglobulin E, eosinophil cationic protein, and eosinophil count with the severity of childhood perennial allergic rhinitis.

BACKGROUND AND PURPOSE: Elevated levels of serum total immunoglobulin E (IgE), serum allergen-specific IgE, serum eosinophil cationic protein (ECP), blood eosinophil count and nasal eosinophil count are considered to be associated with allergic rhinitis (AR), but the relationships between these allergic inflammatory markers and the clinical severity of AR remain controversial. This study aimed to clarify these relationships. METHODS: 186 children aged 2 to 12 years old were selected, including 160 with perennial AR (PAR) and 26 with non-AR as controls. The total nasal symptom score was calculated for each patient from a questionnaire and correlated with data on serum total IgE, serum allergen-specific IgE, serum ECP, and eosinophil count in blood and nasal smear. RESULTS: Levels of all allergic inflammatory markers in children with PAR were significantly different from those in non-allergic children, except for serum ECP. All of the markers were related to the severity of PAR in bivariate correlation analysis. On multiple linear regression analysis, however, only nasal eosinophil count (p<0.001) and serum allergen-specific IgE (p=0.005) were independent predictors. CONCLUSION: These results suggest that nasal eosinophil count, an organ-specific allergic inflammatory marker, and serum allergen-specific IgE, a systemic allergic inflammatory marker, are correlated with the severity of PAR in children.

Animals↗
PubMed1999

The basal plasma histamine level and eosinophil count in allergic and non-allergic patients.

OBJECTIVE: The basal plasma histamine level and eosinophil count in the peripheral blood in patients with a history of allergy (allergic patients) were examined and compared with those in patients without any history of allergy (non-allergic patients). SUBJECTS: We preoperatively examined 70 allergic patients and 70 non-allergic patients who were all scheduled to undergo oral surgery. METHODS: The basal plasma histamine level and eosinophil count in the peripheral blood were measured preoperatively. The high performance liquid chromatography (HPLC) post label system was used to measure the plasma histamine level. RESULTS: The mean basal plasma histamine level in non-allergic patients and allergic patients were 0.31 +/- 0.27 ng/ml and 0.47 +/- 0.30 ng/ml, respectively (p < 0.01). The mean eosinophil counts in non-allergic patients and allergic patients were 3.3 +/- 3.0% and 5.3 +/- 3.4%, respectively (p < 0.01). The patients who had asthma, atopic dermatitis or a food-induced allergy showed a high level of basal plasma histamine compared to that in non-allergic patients. The patients with asthma, allergic rhinitis or atopic dermatitis all demonstrated a higher eosinophil count than non-allergic patients. In addition, the correlation between the plasma histamine level and the eosinophil count was statistically significant (p < 0.05). CONCLUSIONS: The allergic patients had both higher basal plasma histamine levels and eosinophil counts than non-allergic patients (p < 0.01).

Adolescent↗
PubMed1997

Peripheral eosinophil count both before and after liver transplantation predicts acute cellular rejection.

Acute cellular rejection is common after orthotopic liver transplantation and an important cause of graft dysfunction. Eosinophils, potent mediators of tissue damage, have been implicated in the pathogenesis of acute rejection. We studied 55 patients, all of whom had a protocol biopsy 7 days after transplantation and whose peripheral eosinophil count was monitored daily for 11 days after transplantation. Patients were divided clinicopathologically into two groups: group A, without rejection, group B, with rejection. Group B (36% of patients) developed rejection within the 11-day study period. The pretransplant eosinophil count was significantly higher in group B, compared with group A (0.31 +/- 0.08 v 0.10 +/- 0.01 (x10(9)/L), p < .001). After transplantation, the eosinophil count fell to low levels in both groups. By day 3 there was a statistically significant rise in the eosinophil count in group B compared with group A, with a maximum at day 7 [0.51 +/- 0.06 v 0.26 +/- 0.03 (x10(9)/L) p < .001]. After treatment with steroids, the eosinophil count dropped to values similar to those in group A and remained low thereafter in 16 of 20 patients. Four patients had a second episode of rejection; in each of these, eosinophils were raised again and decreased with resolution of the rejection. An eosinophil count threshold of 0.13 (x10(9)/L) before transplantation and 0.33 (x10(9)/L) on day 7 after transplantation predicted the development of rejection (sensitivity 72/70%, specificity 66/63%, negative predictive value 82/79%). We conclude that a raised eosinophil count is associated with acute rejection. The raised eosinophil count before transplantation in group B suggests that these patients are predisposed to acute rejection, and earlier intervention may be indicated.

Adult↗
PubMed1982

[Hypereosinophilia in cancer and cirrhosis : utility of total eosinophil count (author's transl)].

A total eosinophil count (TEC) and a white blood cell count (WBCC) were performed simultaneously in 213 patients. Discrepancies were found between TEC and WBCC. WBCC did not allow detection of hypereosinophilia (TEC exceeding 300 eosinophils/microliter) in 45 patients. Patients were classified in three groups : controls (n = 27), benign disease (n = 65), and apparently cured cancer (n = 36). There was no significant difference between total eosinophil counts for these three groups (Wilcoxon non-parametric test). The incidence of hypereosinophilia (TEC exceeding 300) was similar in the three groups (11%, 14% and 6%). Average TEC levels were determined in 20 patients with decompensated hepatic cirrhosis, in 31 patients with active cancer, and in 14 patients with infection. These levels were significantly different from those found in each of the three previous groups. (Wilcoxon test). The incidence of hypereosinophilia (greater than 300/microliter) was significantly higher among patients with cirrhosis (50%) or active cancer (58%). The possible mechanisms of this hypereosinophilia and it's eventual prognostic utility are considered.

Adolescent↗
PubMed2002

Assessing eosinophil count as a marker of immune activation among human immunodeficiency virus-infected persons in sub-Saharan Africa.

In 611 human immunodeficiency virus-infected persons who had not yet begun to receive antiretroviral therapy, we evaluated the linear association between absolute eosinophil count (as a surrogate for immune response to helminthic infection) and CD4+ T cell count, and between absolute eosinophil count and log virus load. Overall, no significant correlations were observed between eosinophil count and CD4+ T cell count, or between eosinophil count and log virus load.

Adult↗
PubMed2000

The association of sensitization to inhalant allergens with allergy symptoms: the influence of bronchial hyperresponsiveness and blood eosinophil count.

BACKGROUND: We investigated whether the association of allergy symptoms with sensitization to inhalant allergens depends on bronchial hyperresponsiveness, blood eosinophil count, or the degree and nature of sensitization. METHODS: Data on asthma and rhino-conjunctivitis symptoms were obtained from 1904 subjects from a random sample of the Dutch population, aged 20-70 years by the ECRHS questionnaire. Total IgE and specific IgE to four inhalant allergens were measured using CAP System. Bronchial hyperresponsiveness (BHR) was defined as PD20 </= 2 mg methacholine and 'high eosinophil count' as an eosinophil count in the highest quartile. RESULTS: Forty-three percent of the subjects with specific IgE to inhalant allergens was asymptomatic. These subjects had a lower degree of sensitization than symptomatic sensitized subjects and had 'normal' prevalences of BHR and 'high eosinophil count'. Logistic regression showed that the presence of BHR increased the risk of having symptoms for subjects who were sensitized to indoor allergens. Low levels of specific IgE to indoor allergens were only associated with symptoms when BHR was present. Sensitization to outdoor allergens was associated with symptoms at all levels of specific IgE, independently of BHR or eosinophils. CONCLUSION: Our epidemiological data suggest that whether low levels of specific IgE to indoor allergens lead to allergic symptoms is probably determined by the concurrent existence of inflammation of the airways.

Administration, Inhalation↗
PubMed1998

Association between blood eosinophil counts and acute cardiac and pulmonary allograft rejection.

BACKGROUND: Peripheral blood eosinophilia is a particularly early and specific marker of both renal and hepatic allograft rejection. Therefore we evaluated the relationship between blood eosinophil counts and cardiac and pulmonary allograft rejection. METHODS: Differential blood counts were available within 3 days before 383 endomyocardial biopsy specimens in 56 heart transplant recipients. Blood counts were also available before 84 treated rejection episodes and 28 transbronchial biopsy specimens showing no rejection in 58 lung transplant recipients. RESULTS: Cardiac allograft rejection: There was a significant association between the mean maximum blood eosinophil count and treated acute rejection (p < 0.01) and a linear relationship between this eosinophil count and the histologic grade of rejection (p < 0.01). The first increase in eosinophils occurred at a median of 4 days before treated rejection. Pulmonary allograft rejection: The mean maximum blood eosinophil count was 0.14 x 10(9)/L (95% confidence interval = 0.10, 0.18) preceding treated rejection, and this was significantly greater than the mean maximum blood eosinophil count of 0.07 x 10(9)/L (confidence interval = 0.05, 0.09) measured when there was no rejection or during infection (p = 0.01). The first increase in eosinophil occurred at a median of 5 days before treated rejection. There was no relationship between blood neutrophil counts and either cardiac or pulmonary allograft rejection. CONCLUSIONS: An increase in peripheral blood eosinophils but not neutrophils is a specific and early marker of clinically significant rejection of both cardiac and pulmonary allografts. Furthermore, the maximum blood eosinophil count measured in the 3 days before rejection is linearly related to the severity of cardiac allograft rejection.

Adolescent↗